You are here:

clopidogrel 75mg tablets (Plavix)


Following a full submission

clopidogrel (Plavix®) is accepted for restricted use within NHS Scotland for patients with ST segment elevation acute myocardial infarction (MI), in combination with aspirin, in medically treated patients eligible for thrombolytic therapy.

The addition of short-term treatment with clopidogrel to long-term low dose aspirin has improved the patency rate of the infarct related artery as well as clinical endpoints. Treatment with clopidogrel in these patients is restricted to continuation for 4 weeks.

Drug Details

Drug Name: clopidogrel 75mg tablets (Plavix)
SMC Drug ID: 390/07
Manufacturer: Sanofi-Aventis
Indication: ST-segment elevation myocardial infarction (STEMI)
BNF Category:
Sub Category: 2.9 Antiplatelet drugs
Submission Type: Full submission
Status: Restricted
Date Advice Published: 13 August 2007